Effects of ion channel blockers on cell migration in human cardiac c-kit⁺ progenitor cells.

<p><b>(A)</b>: Cell images with acellular wound. The broken lines indicate the initial wound produced with a pipette tip in cells treated with vehicle (control), paxilline (1 M), TTX (1 M), or Ba²⁺ (300 μM). <b>(B)</b>: Ratio of migrated cells in human cardiac c-kit⁺ progenitor cells treated with vehicle, 1 μM paxilline, 1 μM TTX or 300 μM Ba²⁺ (n = 6; *<i>P</i><0.05, **P<0.01 vs. vehicle control). <b>(C)</b>: Images of migrated human cardiac c-kit⁺ progenitor cells on lower surface of the transwell membrane in cells treated with vehicle (control), paxilline (1 M), TTX (1 M) or 300 μM Ba²⁺. <b>(D)</b>: Ratio of migrated human cardiac c-kit⁺ progenitor cells on the lower membrane in cells treated with vehicle (control), paxilline (1 M), TTX (1 M) or 300 μM Ba²⁺ (n = 5; *<i>P</i><0.05, **P<0.01 vs. vehicle control).</p

Effects of silencing KCa1.1 or Kir2.1 on cell proliferation in human cardiac c-kit⁺ progenitor cells.

<p><b>(A)</b>: Cell proliferation was assessed by MTT assay in cells treated with lipofectamine 2000 (Lipo) or transfected with control siRNA (40 nM), KCa1.1 siRNA or Kir2.1 siRNA (10 nM and 40 nM). <b>(B)</b>: [³H]-thymidine incorporation assay was conducted in cells treated with lipofectamine 2000 or transfected with control siRNA, KCa1.1 siRNA, or Kir2.1 siRNA (n = 6 for each group, *P<0.05, **<i>P</i><0.01 vs. control siRNA). (C). Flow cytometry graphs in cells transfected with control siRNA, KCa1.1 siRNA, or Kir2.1 siRNA. <b>(D)</b>: Mean values of different cycle phases in cells treated with lipofectamine, control siRNA, KCa1.1 siRNA, or Kir2.1 siRNA (40 nM each group, n = 6,*<i>P</i><0.05, **<i>P</i><0.01 vs. control siRNA).</p

Effects of silencing KCa1.1 or Kir2.1 on cell migration in human cardiac c-kit⁺ progenitor cells.

<p><b>(A)</b>: Images of human cardiac c-kit⁺ progenitor cells with wound-healing migration assay in confluent cells transfected with control siRNA, KCa1.1 siRNA or Kir2.1 siRNA (40 nM for each group). <b>(B)</b>: Images of migrated human cardiac c-kit⁺ progenitor cells to the lower membrane in cells transfected with control siRNA, KCa1.1 siRNA or Kir2.1 siRNA (40 nM for each group). <b>(C)</b>: Mean values of ratio of migrated cells in cells transfected with control siRNA, KCa1.1 siRNA or Kir2.1 siRNA (40 nM for each group, n = 5 for each group, *<i>P</i><0.05, **<i>P</i><0.01 vs. control siRNA).</p

Inhibition of membrane current by ion channel blockers in human cardiac c-kit⁺ progenitor cells.

<p><b>(A)</b>: BK_Ca and I_Na.TTX were co-expressed in a human cardiac c-kit⁺ progenitor cell, and inhibited respectively by 1 μM paxilline and 30 nM TTX. <b>(B)</b>: I_Kir and BK_Ca were co-expressed in a typical human cardiac c-kit⁺ progenitor cell, and inhibited respectively by 500 μM Ba²⁺ and 1 μM paxilline.</p

Effects of specific siRNA molecules on expression of ion channel genes and proteins in human cardiac c-kit⁺ progenitor cells.

<p><b>(A)</b>: PCR images and relative level of KCa1.1 mRNA in cells treated with lipofectamine 2000 (Lipo), control siRNA, or KCa1.1 siRNA. <b>(B)</b>: Western blots and relative level of KCa1.1 protein in cell treated with lipofectamine 2000, control siRNA, or KCa1.1 siRNA. <b>(C)</b>: PCR images and relative level of Kir2.1 mRNA in cells treated with lipofectamine 2000, control siRNA, or Kir2.1 siRNA. <b>(D)</b>: Western blots and relative level of Kir2.1 protein in cell treated with lipofectamine 2000, control siRNA, or Kir2.1 siRNA (n = 6 for each group, **<i>P</i><0.01 vs. control siRNA).</p

Supplementary document for Transmission rate Optimized by dynamic resource allocation algorithm for RF/VLC heterogeneous networks - 5426108.pdf

Application for additional co-autho

Effects of silencing KCa1.1 or Kir2.1 on cell migration in human cardiac c-kit⁺ progenitor cells.

<p><b>(A)</b>: Images of human cardiac c-kit⁺ progenitor cells with wound-healing migration assay in confluent cells transfected with control siRNA, KCa1.1 siRNA or Kir2.1 siRNA (40 nM for each group). <b>(B)</b>: Images of migrated human cardiac c-kit⁺ progenitor cells to the lower membrane in cells transfected with control siRNA, KCa1.1 siRNA or Kir2.1 siRNA (40 nM for each group). <b>(C)</b>: Mean values of ratio of migrated cells in cells transfected with control siRNA, KCa1.1 siRNA or Kir2.1 siRNA (40 nM for each group, n = 5 for each group, *<i>P</i><0.05, **<i>P</i><0.01 vs. control siRNA).</p

Effects of ion channel blockers on cell proliferation in human cardiac c-kit⁺ progenitor cells.

<p><b>(A)</b>: cell proliferation was assessed by MTT assay in cells treated with vehicle (V), paxilline, TTX or Ba²⁺ at concentrations as indicated (n = 8, *<i>P</i><0.05, **<i>P</i><0.01 vs. vehicle control). <b>(B)</b>: [³H]-thymidine incorporation assay was conducted in cells treated with paxilline, TTX or Ba²⁺ at different concentrations (n = 6, *<i>P</i><0.05, **<i>P</i><0.01 vs. vehicle control).</p

Data for: Chinese Medicine JQ Granule Combined with Half-dose Omeprazole for Non-erosive Reflux Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Study Protocol

Data for: Chinese Medicine JQ Granule Combined with Half-dose Omeprazole for Non-erosive Reflux Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Study Protoco